IRD
Opus Genetics, Inc.
4.40$
-4.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -0.4% | -3.9% | -13.5% | -9.9% | -8.7% | +30.7% | -19.7% | -6.6% | +39.1% | +32.9% | +39.2% | |
| – | -0.4% | -3.9% | -13.5% | -9.9% | -9.4% | +30.9% | -19.8% | -6.6% | +39.4% | +33.1% | +39.2% | |
| – | +19.2% | -6.6% | -12.2% | -11.5% | -17.2% | +37.8% | -22.4% | -5.0% | +46.3% | +33.0% | +48.1% | |
| – | +19.3% | -6.6% | -12.2% | -11.5% | -17.2% | +37.8% | -22.4% | -5.0% | +46.3% | +33.0% | +48.1% | |
| – | -79.4% | +33.6% | -26.0% | +44.2% | +73.6% | -17.6% | -3.7% | -6.5% | -26.1% | -14.2% | -46.4% | |
| – | +3.4% | +43.2% | -27.5% | +45.0% | +395.0% | +43.0% | -50.8% | +42.3% | +15.7% | +222.7% | -5.9% | |
| – | +3.4% | +43.2% | -27.5% | +45.0% | +85.5% | +114.7% | -16.7% | +44.1% | -73.2% | +20.0% | -18.6% | |
| – | +13.9% | -4.1% | -69.3% | +33.1% | +273.0% | -22.8% | -39.7% | +63.5% | +37.5% | +34.3% | -57.5% | |
| – | – | – | – | – | – | – | – | +6.8% | +5.7% | +6.1% | +2,922.0% | |
| – | -0.7% | -7.7% | -11.8% | -15.6% | -80.4% | -24.6% | +244.4% | -65.9% | +157.2% | -398.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.8% | +11.5% | +5.3% | +1.2% | +20.8% | +7.3% | +87.0% | +11.5% | +780.9% | +39.6% | -87.2% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.